Roche (RHHBY) is actively engaging with the U.S. administration to secure exemptions from import tariffs. The Swiss pharmaceutical giant is making the case that its imports to the U.S. are counterbalanced by its exports of American-manufactured drugs and diagnostics.
During a press call following the announcement of the first quarter earnings, Roche's CEO, Thomas Schinecker, explained that as long as the company maintains an equal balance by producing in the U.S. what it imports, it should remain unaffected by tariffs. This balance forms the crux of Roche's ongoing discussions with the U.S. government.
Schinecker also highlighted that Roche is actively communicating with various government levels, emphasizing that the push for domestic production of all goods consumed in the U.S. could lead to increased manufacturing costs. The company's strategic approach seeks to mitigate the impact of potential tariffs on its operations and uphold competitive pricing.
